Experiences and Perspectives of GC-MS Application for the Search of Low Molecular Weight Discriminants of Schizophrenia
-
Published:2022-12-31
Issue:1
Volume:28
Page:324
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Porozova NataliaORCID,
Danilova ElenaORCID,
Senshinov Igor,
Tsakalof AndreasORCID,
Nosyrev Alexander
Abstract
Schizophrenia is one of the most severe chronic mental disorders that is currently diagnosed and categorized through subjective clinical assessment of complex symptoms. At present, there is a recognized need for an objective, unbiased clinical test for schizophrenia diagnosis at an early stage and categorization of the disease. This can be achieved by assaying low-molecular-weight biomarkers of the disease. Here we give an overview of previously conducted research on the discovery of biomarkers of schizophrenia and focus on the studies implemented with the use of GC-MS and the least invasiveness of biological samples acquisition. The presented data demonstrate that GC-MS is a powerful instrumental platform for investigating dysregulated biochemical pathways implicated in schizophrenia pathogenesis. With this platform, different research groups suggested a number of low molecular weight biomarkers of schizophrenia. However, we recognize an inconsistency between the biomarkers or biomarkers patterns revealed by different groups even in the same matrix. Moreover, despite the importance of the problem, the number of relevant studies is limited. The intensification of the research, as well as the harmonization of the analytical procedures to overcome the observed inconsistencies, can be indicated as future directions in the schizophrenia bio-markers quest.
Funder
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russian Federation
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference72 articles.
1. Why sex differences in schizophrenia?;Li;J. Transl. Neurosci.,2016
2. Psychiatric comorbidities and schizophrenia;Buckley;Schizophr. Bull.,2009
3. Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study;Crump;Am. J. Psychiatry,2013
4. WHO (2022, January 18). Schizophrenia Key Facts. Available online: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
5. The cost of mental disorders: A systematic review;Christensen;Epidemiol. Psychiatr. Sci.,2020